<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/253520-a-hemostat-to-provide-and-maintain-effective-hemostasis by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 12:41:39 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 253520:A HEMOSTAT TO PROVIDE AND MAINTAIN EFFECTIVE HEMOSTASIS</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">A HEMOSTAT TO PROVIDE AND MAINTAIN EFFECTIVE HEMOSTASIS</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>This invention relaters to a hemostat to provide and maintain effective hemostasis, comprising an absorbable foam, an absorbable woven or knitted fabric, and thrombin and/or fibrinogen, wherein the foam comprises carboxymethyl cellulose and albumin, the ratio of carboxymethyl cellulose to the albumin ranges from about 1:8 to 8:1 by weight, wherein the absorbable woven or knitted fabric preferably comprises oxidized regenerated cellulose and may have a basis weight ranging from about 0.001 to 0.2 g/in2, and wherein the thrombin activity on the hemostat ranges from about 20 to 500 IU/cm2, and/or the fibrinogen activity ranges from about 2 to 15 mg/cm2.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>FIELD OF THE INVENTION<br>
The present invention relates to a hemostat.		<br>
BACKGROUND OF THE INVENTION<br>
The control of bleeding, as well as sealing of air and various bodily fluids, is<br>
essential and critical in surgical procedures to minimize blood loss, to seal tissue and<br>
organ structures, to reduce post-surgical complications, and to shorten the duration of<br>
the surgery in the operating room.<br>
In an effort to provide dressings with enhanced hemostatic and tissue sealing<br>
and adhering properties, therapeutic agents, including, but not limited to, thrombin,<br>
fibrin and fibrinogen have been combined with dressing carriers or substrates, including<br>
gelatin-based carriers, polysaccharide-based carriers, glycolic acid or lactic acid-based<br>
carriers and a collagen matrix. Examples of such dressings are disclosed in USP<br>
6,762,336, USP 6,733,774 and PCT publication WO 2004/064878 A1.<br>
Due to its biodegradability and its bactericidal, tissue sealing, tissue repairing,<br>
drug delivering and hemostatic properties, it is desirable to utilize cellulose that has<br>
been oxidized to contain carboxylic acid moieties, hereinafter referred to as carboxylic-<br>
oxidized cellulose, as a topical dressing in a variety of surgical procedures, including<br>
neurosurgery, abdominal surgery, cardiovascular surgery, thoracic surgery, head and<br>
neck surgery, pelvic surgery and skin and subcutaneous tissue procedures.<br>
However, when carboxylic-oxidized cellulose is utilized in combination with<br>
thrombin and/or fibrinogen, the acidic moieties that may be present in the cellulose<br>
denature the activity of the thrombin and/or fibrinogen. Therefore, it is desirable to<br>
shield the thrombin and/or fibrinogen from such acid moieties to maintain their<br>
hemostatic activities.<br><br>
SUMMARY OF THE INVENTION<br>
The present invention is directed towards a hemostat comprising an absorbable<br>
foam, an absorbable woven or knitted fabric, thrombin and/or fibrinogen.<br>
DETAILED DESCRIPTION OF THE INVENTION<br>
The hemostat described herein provides and maintains effective hemostasis<br>
when applied to a wound requiring hemostasis. Effective hemostasis, as used herein, is<br>
the ability to control and/or abate capillary, venous, or arteriole bleeding within an<br>
effective time, as recognized by those skilled in the art of hemostasis. Further<br>
indications of effective hemostasis may be provided by governmental regulatory<br>
standards and the like.<br>
In certain embodiments, hemostats of the present invention are effective in<br>
providing and maintaining hemostasis in cases of severe or brisk bleeding. As used<br>
herein, severe bleeding is meant to include those cases of bleeding where a relatively<br>
high volume of blood is lost at a relatively high rate. Examples of severe bleeding<br>
include, without limitation, bleeding due to arterial puncture, liver resection, blunt liver<br>
trauma, blunt spleen trauma, aortic aneurysm, bleeding from patients with over-<br>
anticoagulation, or bleeding from patients with coagulopathies, such as hemophilia.<br>
The hemostat generally comprises an absorbable foam and a reinforcement<br>
fabric. The reinforcement fabric provides a backing to which the foam may be<br>
attached, either directly or indirectly, wherein thrombin and/or fibrinogen may be<br>
substantially homogeneously dispersed throughout the foam and / or disposed on the<br>
surface of the foam. The reinforcement fabric provides strength to the hemostat<br>
sufficient to permit the user to place and manipulate the hemostat on or within a wound<br>
or directly onto tissue of a patient requiring hemostasis, or tissue sealing and adhering.<br>
In embodiments where the foam is directly attached to the reinforcement fabric,<br>
fibrinogen may be substantially homogeneously dispersed throughout the foam and/or<br>
disposed on the surface of the foam. Alternatively, thrombin may be disposed on the<br>
surface of the foam.<br><br>
In embodiments where the foam is indirectly attached to the reinforcement<br>
fabric, fibrinogen and/or thrombin may be substantially homogeneously dispersed<br>
throughout the foam and or disposed on the surface of the foam.<br>
In addition to serving as a carrier for the thrombin and/or fibrinogen, the foam<br>
also serves to shield the thrombin and/or fibrinogen from acidic moieties that may be<br>
present in the reinforcement fabric, such as is the case where carboxylic-oxidized<br>
cellulose is used as the reinforcement fabric.<br>
The foam may be a biocompatible, water-soluble, or water-swellable polymer<br>
and optionally a foaming agent/surfactant. Preferred biocompatible, water-soluble, or<br>
water-swellable polymers used to fabricate the foam include polysaccharides. Such<br>
polysaccharides include, without limitation, cellulose, alkyl cellulose, e.g.<br>
methylcellulose, alkylhydroxyalkyl cellulose, hydroxyalkyl cellulose, cellulose sulfate,<br>
salts of carboxymethyl cellulose, carboxymethyl cellulose, and carboxyethyl cellulose.<br>
Additionally, albumin, chitin, carboxymethyl chitin, hyaluronic acid, salts of hyaluronic<br>
acid, alginate, alginic acid, propylene glycol alginate, glycogen, dextran, dextran<br>
sulfate, curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates,<br>
carboxymethyl dextran, carboxymethyl chitosan, chitosan, heparin, heparin sulfate,<br>
heparan, heparan sulfate, dermatan sulfate, keratan sulfate, carrageenans, chitosan,<br>
starch, amylose, amylopectin, poly-N-glucosamine, polymannuronic acid,<br>
polyglucuronic acid polyguluronic acid, and derivatives of any of the above, may be<br>
utilized. Even more preferably, biocompatible, water-soluble, or water-swellable<br>
polymers are an alkali or alkali earth metal salts of carboxylmethyl cellulose, most<br>
preferably sodium carboxylmethyl cellulose (CMC-Na).<br>
The foaming agent/surfactant may be a cationic, anionic, amphoteric,<br>
zwitterionic or nonionic surfactant, or natural or modified proteins, including but<br>
without limitation, albumin, sodium lauryl sulfate, sodium laureth sulfate, or ammonia<br>
lauryl sulfate. A preferred foaming agent/surfactant is albumin, and more preferably,<br>
human serum albumin (HSA).<br><br>
The reinforcement fabric is an absorbable woven or knitted fabric and comprises<br>
oxidized polysaccharides, in particular oxidized cellulose and the neutralized<br>
derivatives thereof. For example, the cellulose may be carboxylic-oxidized or<br>
aldehyde-oxidized cellulose. More preferably, oxidized regenerated polysaccharides,<br>
including but without limitation oxidized regenerated cellulose, may be used to prepare<br>
the absorbable woven or knitted fabric. Regenerated cellulose is preferred due to its<br>
higher degree of uniformity versus cellulose that has not been regenerated. Regenerated<br>
cellulose and a detailed description of how to make oxidized regenerated cellulose are<br>
set forth in USP 3,364,200, USP 5,180,398 and USP 4,626,253, the contents each of<br>
which is hereby incorporated by reference as if set forth in its entirety.<br>
Examples of fabrics that may be utilized as the reinforcement fabric include, but<br>
are not limited to, Interceed® absorbable adhesion barrier, Surgicel® absorbable<br>
hemostat, Surgicel Nu-Knit® absorbable hemostat and Surgicel® Fibrillar absorbable<br>
hemostat (each available from Johnson &amp; Johnson Wound Management Worldwide or<br>
Gynecare Worldwide, each a division of Ethicon, Inc., Somerville, New Jersey).<br>
The reinforcement fabric utilized in the present invention may be woven or<br>
knitted, provided that the fabric possesses the physical properties necessary for use in<br>
contemplated applications. Such fabrics, for example, are described in USP 4,626,253,<br>
USP 5,002,551 and USP 5,007,916, the contents of which are hereby incorporated by<br>
reference herein as if set forth in its entirety. In preferred embodiments, the<br>
reinforcement fabric is a warp knitted tricot fabric constructed of bright rayon yarn that<br>
is subsequently oxidized to include carboxyl or aldehyde moieties in amounts effective<br>
to provide the fabrics with biodegradability.<br>
In an alternative embodiment, the reinforcement fabric comprises oxidized<br>
polysaccharide fibers in combination with fibers comprised of aliphatic polyester<br>
polymers, copolymers, or blends thereof.<br><br>
Aliphatic polyester polymers include, but are not limited to homopolymers and<br>
copolymers of lactide (which includes lactic acid, D-, L- and meso lactide), glycolide<br>
(including glycolic acid), epsilon-caprolactone, p-dioxanone (l,4-dioxan-2-one),<br>
trimethylene carbonate (1, 3-dioxan-2-one), alkyl derivatives of trimethylene carbonate,<br>
delta-valerolactone, beta-butyrolactone, gamma-butyrolactone, epsilon- decalactone,<br>
hydroxybutyrate (repeating units), hydroxyvalerate (repeating units), l,4-dioxepan-2-<br>
one (including its dimer 1,5, 8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-<br>
2-one, 6,6-dimethyl-1, 4-dioxan-2-one 2,5-diketomorpholine, pivalolactone, alpha,<br>
alpha- diethylpropiolactone, ethylene carbonate, ethylene oxalate, 3-methyl-1,4-<br>
dioxane-2,5-dione, 3,3-diethyl-1,4-dioxan-2,5-dione, 6,8- dioxabicycloctane-7- one and<br>
polymer blends thereof.<br>
The reinforcement fabric preferably comprises oxidized regenerated cellulose<br>
and may have a basis weight ranging from about 0.001 to 0.2 g/in2, preferably in the<br>
range of about 0.01 to 0.1 g/in2, and most preferably in the range of about 0.04 to 0.07<br>
g/in2.<br>
In preparing the hemostats, a foam slurry may be prepared from, for example,<br>
CMC-Na and HSA, and then spread on the surface of, for example, an oxidized<br>
regenerated cellulose fabric. The ratio of the water-soluble or water-swellable polymer<br>
to the foaming agent may range from about 1:8 to 8:1 by weight, and preferably from<br>
about 2:1 to 1:2 by weight. The foam slurry is then dried either by lyophilization or in<br>
an oven at elevated temperature to form a solid foam substrate. The foam substrate<br>
may be treated with a chemical cross-1inking agent such as glutaraldehyde for increased<br>
strength or may be partly cross-1inked by heating. The density of the hemostat may be<br>
from about 5 to 20 mg/cm3.<br>
The thrombin and/or fibrinogen may be animal derived, preferably human, or<br>
may be recombinant. The thrombin activity on the hemostat may be in the range of<br>
about 20 to 500 IU/cm2, preferably about 20 to 200 IU/cm2, and most preferably about<br>
50 to 200 IU/cm2. The fibrinogen activity on the hemostat may be in the range of about<br><br>
2 to 15 mg/cm2, preferably about 3 to 10 mg/cm2, and most preferably about 4 to 7<br>
mg/cm2.<br>
Thrombin powders may be prepared by lyophilization of thrombin solutions.<br>
Fibrinogen may be prepared by lyophilizaton of solutions containing fibrinogen, such as<br>
those described in USP 6,121,232 and PCT Application Publication No. WO<br>
02/095019. Dry powders of fibrinogen and thrombin suspended in an organic solvent<br>
such as PF5060 or HFE 7000—7300 series are then sprayed onto the surface of the<br>
foam. Alternatively, the thrombin and/or fibrinogen may be incorporated into the foam<br>
during the foam production.<br>
In an alternate embodiment, the hemostat may comprise a first foam having<br>
incorporated thereon or therein a first therapeutic agent, e.g., fibrinogen, and a second<br>
foam separate (unattached) from the first foam that may have upon or incorporated<br>
therein powders of a second therapeutic agent, e.g. thrombin.<br>
In an alternative embodiment, a hemostat may comprise a reinforcement fabric<br>
having a first foam adjacent thereto and second foam on the other side of the first foam.<br>
Fibrinogen may be incorporated into or onto the first foam. While either thrombin or<br>
fibrinogen may be incorporated into or onto the second foam, thrombin is preferred. In<br>
such an embodiment, the foam slurries used to prepare the first and second foams are<br>
selected such that the second foam is less dense than the first foam so that it liquefies or<br>
melts quickly after coming into contact with blood at the wound site to start the clotting<br>
process. The second foam contacts the bleeding site first, then the combined<br>
reinforcing layer and first foam keeps the clot from being washed away by the blood<br>
flow.<br>
In another alternative embodiment, the hemostat may comprise a foam having<br>
incorporated thereon or therein thrombin and/or fibrinogen, a nonwoven, and a<br>
reinforcement fabric wherein the foam is indirectly attached to the reinforcement fabric<br>
via the nonwoven. The nonwoven may be comprised of aliphatic polyester fibers such<br>
as those described herein.<br><br>
The hemostat comprising a foam having incorporated thereon or therein<br>
thrombin and/or fibrinogen, a nonwoven, and a reinforcement fabric wherein the foam<br>
is indirectly attached to the reinforcement fabric via the nonwoven may be prepared in<br>
the following manner. A nonwoven comprising a copolymer of lactide and glycolide is<br>
needlepunched to the oxidized regenerated cellulose reinforcement fabric. An aqueous<br>
solution of about 0.2 to about 1.5% hyaluronic acid and thrombin is prepared. The<br>
aqueous solution is then spread upon the surface of the nonwoven such that it partially<br>
penetrates the nonwoven. The solution layer is foamed by lyophilization.<br>
The nonwoven is made by processes other than spinning, weaving or knitting.<br>
For example, the nonwoven may be prepared from yarn, scrims, netting, fibers or<br>
filaments that have been made by processes that include spinning, weaving or knitting.<br>
The yarn, scrims, netting fibers and/or filaments are crimped to enhance entanglement<br>
with each other. Such crimped yarn, scrims, netting fibers and/or filaments may then be<br>
cut into staple that is long enough to entangle. The staple may be carded to create<br>
nonwoven bats, which may be then needlepunched or calendared. Additionally, the<br>
staple may be kinked or piled. Other methods known for the production of nonwovens<br>
may be utilized and include such processes as air laying, wet forming and stitch<br>
bonding.<br>
The hemostat may optionally include without limitation, procoagulant enzymes,<br>
proteins and peptides, may be naturally occurring, recombinant, or synthetic, and may<br>
be selected from the group consisting of prothrombin, fibrin, fibronectin, heparinase,<br>
Factor X/Xa, Factor VII/VIIa, Factor IX/IXa, Factor XI/XIa, Factor XII/XIIa, tissue<br>
factor, batroxobin, ancrod, ecarin, von Willebrand Factor, collagen, elastin, albumin,<br>
gelatin, platelet surface glycoproteins, vasopressin and vasopressin analogs,<br>
epinephrine, selectin, procoagulant venom, plasminogen activator inhibitor, platelet<br>
activating agents, synthetic peptides having hemostatic activity, derivatives of the above<br>
and any combination thereof.<br>
The hemostat described herein may also be used as an adjunct to primary wound<br>
closure devices, such as arterial closure devices, staples, and sutures, to seal potential<br><br>
leaks of gasses, liquids, or solids as well as to provide hemostasis. For example, the<br>
hemostat may be utilized to seal air from tissue or fluids from organs and tissues,<br>
including but not limited to, bile, lymph, cerebrospinal fluids, gastrointestinal fluids,<br>
interstitial fluids and urine.<br>
The hemostat described herein has additional medical applications and may be<br>
used for a variety of clinical functions, including but not limited to tissue<br>
reienforcement and buttressing, i.e., for gastrointestinal or vascular anastomoses,<br>
approximation, i.e., to connect anastomoses that are difficult to perform (i.e. under<br>
tension), and tension releasing. The hemostat may additionally promote and possibly<br>
enhance the natural tissue healing process in all the above events. This hemostat can be<br>
used internally in many types of surgery, including, but not limited to, cardiovascular,<br>
peripheral-vascular, cardio-thoracic, gynecological, neuro- and general surgery. The<br>
hemostat may also be used to attach medical devices (e.g. meshes, clips and films) to<br>
tissues, tissue to tissue, or medical device to medical device.<br>
Example 1. Lyophilized CMC-Na/ HSA foam with ORC fabric<br>
In a mixing bowl were added 190 mL of a 2% solution of sodium carboxy<br>
methylcellulose (CMC-Na) (Aqualon, catalog No. 7M8SFPH) and 10 mL of a 20%<br>
solution of human serum albumin (HSA) (ALBUTEIN™, Alpha Therapeutic<br>
Corporation). The mixture was whipped mechanically to generate a foamed slurry.<br>
The foamed slurry was transferred to a rectangular frame having a piece of knitted<br>
carboxylic-oxidized regenerated cellulose fabric, available from Ethicon, Inc. under the<br>
tradename Interceed®, disposed at the bottom. The foamed slurry was then spread<br>
evenly across the whole frame to yield a thickness of about 3 mm. The foamed slurry<br>
was then lyophilized to remove solvent, thus yielding a solid CMC-Na/HSA foam<br>
adjacent and attached to the ORC fabric.<br>
Example 2. Heat-treated CMC-Na/ HSA foam with ORC fabric<br>
In a mixing bowl were added 190 mL of 2% solution of sodium carboxy<br>
methylcellulose (CMC-Na) (Aqualon, catalog No. 7M8SFPH) and 10 mL of 20%<br>
solution of human serum albumin (HSA) (ALBUTEIN™, Alpha Therapeutic<br><br>
Corporation). The mixture was whipped mechanically to generate a foamed slurry.<br>
The foamed slurry was transferred to a rectangular frame having a piece of carboxylic-<br>
oxidized regenerated cellulose fabric, available from Ethicon, Inc. under the tradename<br>
Interceed®, at the bottom. The foamed slurry was then spread evenly across the whole<br>
frame to yield a thickness of about 3 mm. The foamed slurry was then heated in an<br>
oven at 65°C for an hour to remove solvent and thus yielded a solid CMC-Na/HSA<br>
foam adjacent and attached to the ORC fabric.<br>
Example 3. Reinforced Foams with active clotting factors<br>
Hemostatic agents were applied to the constructs prepared in Examples 1 and 2<br>
as below. The constructs were cut into 3" x 4" pieces. Lyophilized thrombin and<br>
Biological Active Components 2 (BAC-2) containing fibrinogen were ground to<br>
powder separately. The thrombin powder and the BAC-2 powder were passed through<br>
a 45-micrometer sieve. The two powders were weighed to provide a final fibrinogen<br>
concentration of 6 mg/cm2, 7 mg/cm2 or 8 mg/cm2, and a thrombin activity of 50<br>
IU/cm2. The powders were then mixed and suspended in a per-fluorinated solvent HFE<br>
7000 in a flask. The suspension then was sprayed onto the various constructs and then<br>
dried under nitrogen at room temperature for 1 hour.<br>
Example 4. Hemostasis test in a swine spleen linear incision model<br>
Linear incisions (1.5 cm long and 0.3 cm deep) were made on a swine spleen.<br>
After spraying the wound with 0.9% saline solution, various test materials from<br>
Example 3 were applied to the wounds. Tamponade was applied for 30 seconds<br>
followed by a 30-second observation. When hemostasis was not achieved, additional<br>
tamponade was applied to stop the bleeding. A piece of surgical gauze and a<br>
commercial product Tachocomb® surgical patch (commercially available from<br>
Nycomed Pharma GmbH) were used as controls. Table 1 lists the experimental results.<br><br><br><br>
Example 5. CMC-Na/HSA foam with thrombin<br>
In a mixing bowl were added 190 mL of a 2% solution of sodium carboxy<br>
methylcellulose (CMC-Na) (Aqualon, catalog No. 7M8SFPH) and 10 mL of a 20%<br>
solution of human serum albumin (HSA) (ALBUTEIN™, Alpha Therapeutic<br>
Corporation). The mixture was whipped mechanically to generate a foamed slurry. A<br>
portion of the foamed slurry was transferred to a glass beaker. Thrombin powder was<br>
folded into the foamed slurry to yield an estimated activity of 1,000 IU/cm3. The final<br>
mixture was lyophilized in aluminum weighing dishes with a height of 0.5 cm to form a<br>
solid foam comprising the thrombin dispersed therethrough.<br>
Example 6. CMC-Na/HSA foam with fibrinogen<br>
In a mixing bowl were added 190 mL of 2% solution of sodium carboxy<br>
methylcellulose (CMC-Na) (Aqualon, catalog No. 7M8SFPH) and 10 mL of 20%<br>
solution of human serum albumin (HSA) (ALBUTEIN™, Alpha Therapeutic<br>
Corporation). The mixture was whipped mechanically to generate a foamed slurry. A<br>
portion of the foamed slurry was transferred to a glass beaker. Five grams of fibrinogen<br>
powder was folded into the foam. The final mixture was placed in an aluminum<br>
weighing dish with a height of 0.5 cm and a having a piece of ORC fabric at the<br>
bottom. The foamed slurry then was lyophilized to form a solid foam comprising the<br>
fibrinogen dispersed therethrough.<br><br>
Example 7. Hemostasis test with CMC-Na/HSA/Thrombin foam and CMC-<br>
Na/HSA/Fibrinogen foam<br>
A severe bleeding wound was made on a swine liver. The defect was created by<br>
making a triangular cut with a surgical scalpel. Each side measured about 1 inch and<br>
the depth measured 5mm. After the triangular liver tissue was removed, CMC-<br>
Na/HSA/Thrombin foam (1" x 1") was quickly applied to the wound. A piece of CMC-<br>
Na/HSA/Fibrinogen foam was then applied on top of the thrombin foam followed by<br>
manual compression. Hemostasis was achieved in 2 minutes.<br><br>
WE CLAIM<br>
1.	A hemostat to provide and maintain effective hemostasis, comprising an<br>
absorbable foam, an absorbable woven or knitted fabric, and thrombin and/or<br>
fibrinogen, wherein the foam comprises carboxymethyl cellulose and albumin,<br>
the ratio of carboxymethyl cellulose to the albumin ranges from about 1:8 to<br>
8:1 by weight, wherein the absorbable woven or knitted fabric preferably<br>
comprises oxidized regenerated cellulose and may have a basis weight<br>
ranging from about 0.001 to 0.2 g/in2, and wherein the thrombin activity on<br>
the hemostat ranges from about 20 to 500 IU/cm2, and/or the fibrinogen<br>
activity ranges from about 2 to 15 mg/cm2.<br>
2.	The hemostat as claimed in claim 1, wherein the foam comprises one or more<br>
polymers selected from the group consisting of polysaccharides, albumin,<br>
chitin, carboxymethyl chitin, hyaluronic acid, salts of hyaluronic acid, alginate,<br>
alginic acid, propylene glycol alginate, glycogen, dextran, dextran sulfate,<br>
curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates,<br>
carboxymethyl dextran, carboxymethyl chitosan, chitosan, heparin, heparin<br>
sulfate, heparan, heparan sulfate, dermatan sulfate, keratin sulfate,<br>
carrageenans, chitosan, starch, amylose, amylopectin, poly-N-glucosamine,<br>
polymannuronic acid, polyglucuronic acid polyguluronic acid, and derivatives<br>
of any of the above.<br>
3.	The hemostat as claimed in claim 2, wherein the foam comprises a<br>
polysaccharide selected from the group consisting of methylcellulose,<br>
alkylhydroxyalkyl cellulose, hydroxyalkyl cellulose, cellulose sulfate, salts of<br>
carboxymethyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose.<br><br>
4.	The hemostat as claimed in claim 1, wherein the absorbable woven or knitted<br>
fabric comprises oxidized regenerated cellulose, and the thrombin and/or<br>
fibrinogen are incorporated into or sprayed onto the foam.<br>
5.	The hemostat as claimed in claim 2, wherein the foam comprises hyaluronic<br>
acid or salts thereof and thrombin and/or fibrinogen is incorporated into the<br>
foam.<br>
6.	The hemostat as claimed in any one of claims 1 to 5, wherein the hemostat is<br>
sterilized.<br>
7.	The hemostat as claimed in claim 6, wherein the hemostat is sterilized by<br>
electron beam sterilization to a sterility assurance level of 10-6 with an<br>
absorbed dose from 4 to 25 kGy.<br><br><br>
ABSTRACT<br><br>
TITLE : "A HEMOSTAT TO PROVIDE AND MAINTAIN EFFECTIVE<br>
HEMOSTASIS"<br>
This invention relaters to a hemostat to provide and maintain effective<br>
hemostasis, comprising an absorbable foam, an absorbable woven or knitted<br>
fabric, and thrombin and/or fibrinogen, wherein the foam comprises<br>
carboxymethyl cellulose and albumin, the ratio of carboxymethyl cellulose to the<br>
albumin ranges from about 1:8 to 8:1 by weight, wherein the absorbable woven<br>
or knitted fabric preferably comprises oxidized regenerated cellulose and may<br>
have a basis weight ranging from about 0.001 to 0.2 g/in2, and wherein the<br>
thrombin activity on the hemostat ranges from about 20 to 500 IU/cm2, and/or<br>
the fibrinogen activity ranges from about 2 to 15 mg/cm2.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzMzgta29sbnAtMjAwNy1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">01338-kolnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzMzgta29sbnAtMjAwNy1jbGFpbXMxLjAucGRm" target="_blank" style="word-wrap:break-word;">01338-kolnp-2007-claims1.0.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzMzgta29sbnAtMjAwNy1jbGFpbXMxLjEucGRm" target="_blank" style="word-wrap:break-word;">01338-kolnp-2007-claims1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzMzgta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">01338-kolnp-2007-correspondence others 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzMzgta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">01338-kolnp-2007-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzMzgta29sbnAtMjAwNy1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">01338-kolnp-2007-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzMzgta29sbnAtMjAwNy1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">01338-kolnp-2007-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzMzgta29sbnAtMjAwNy1mb3JtIDIucGRm" target="_blank" style="word-wrap:break-word;">01338-kolnp-2007-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzMzgta29sbnAtMjAwNy1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">01338-kolnp-2007-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzMzgta29sbnAtMjAwNy1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">01338-kolnp-2007-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzMzgta29sbnAtMjAwNy1ncGEucGRm" target="_blank" style="word-wrap:break-word;">01338-kolnp-2007-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzMzgta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">01338-kolnp-2007-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEzMzgta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHNlYXJjaCByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">01338-kolnp-2007-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LSgyNy0wMS0yMDEyKS1BQlNUUkFDVC5wZGY=" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-(27-01-2012)-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LSgyNy0wMS0yMDEyKS1BTUFOREVEIENMQUlNUy5wZGY=" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-(27-01-2012)-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LSgyNy0wMS0yMDEyKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-(27-01-2012)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LSgyNy0wMS0yMDEyKS1ERVNDUklQVElPTiAoQ09NUExFVEUpLnBkZg==" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-(27-01-2012)-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LSgyNy0wMS0yMDEyKS1GT1JNIDEucGRm" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-(27-01-2012)-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LSgyNy0wMS0yMDEyKS1GT1JNIDIucGRm" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-(27-01-2012)-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LSgyNy0wMS0yMDEyKS1QQS5wZGY=" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-(27-01-2012)-PA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xucC0yMDA3LUFCU1RSQUNUIDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1338-KOLnp-2007-ABSTRACT 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xucC0yMDA3LUFNQU5ERUQgQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">1338-KOLnp-2007-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUFTU0lHTk1FTlQucGRm" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFIDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-CORRESPONDENCE 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xucC0yMDA3LURFU0NSSVBUSU9OIChDT01QTEVURSkgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">1338-KOLnp-2007-DESCRIPTION (COMPLETE) 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xucC0yMDA3LUVYQU1JTkFUSU9OIFJFUE9SVCBSRVBMWSBSRUNJRVZFRC5wZGY=" target="_blank" style="word-wrap:break-word;">1338-KOLnp-2007-EXAMINATION REPORT REPLY RECIEVED.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xucC0yMDA3LUZPUk0gMS0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1338-KOLnp-2007-FORM 1-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUZPUk0gMTggMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-FORM 18 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1rb2xucC0yMDA3LWZvcm0gMTgucGRm" target="_blank" style="word-wrap:break-word;">1338-kolnp-2007-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xucC0yMDA3LUZPUk0gMi0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1338-KOLnp-2007-FORM 2-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUZPUk0gMjYucGRm" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-FORM 26.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUZPUk0gMyAxLjEucGRm" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-FORM 3 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xucC0yMDA3LUZPUk0gMy0xLjEucGRm" target="_blank" style="word-wrap:break-word;">1338-KOLnp-2007-FORM 3-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUZPUk0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-FORM 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUdSQU5URUQtQUJTVFJBQ1QucGRm" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-GRANTED-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUdSQU5URUQtQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-GRANTED-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUdSQU5URUQtREVTQ1JJUFRJT04gKENPTVBMRVRFKS5wZGY=" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-GRANTED-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-GRANTED-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-GRANTED-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUdSQU5URUQtU1BFQ0lGSUNBVElPTi5wZGY=" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-GRANTED-SPECIFICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LUlOVEVOQVRJT05BTCBQVUJMSUNBVElPTi5wZGY=" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-INTENATIONAL PUBLICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xucC0yMDA3LU9USEVSUyAxLjEucGRm" target="_blank" style="word-wrap:break-word;">1338-KOLnp-2007-OTHERS 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LVBFVElUSU9OIFVOREVSIFJVTEUgMTM3LnBkZg==" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LVBFVElUSU9OIFVOREVSIFJVTFIgMTM3LTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-PETITION UNDER RULR 137-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTMzOC1LT0xOUC0yMDA3LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">1338-KOLNP-2007-REPLY TO EXAMINATION REPORT.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="253519-histamine-h3-receptor-agents-preparation-and-therapeutic-uses.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="253521-binder-comprising-on-aqueous-film-forming-polymeric-siloxane.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>253520</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1338/KOLNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>30/2012</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>27-Jul-2012</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>26-Jul-2012</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>17-Apr-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>OMRIX BIOPHARMACEUTICAL, INC</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>CHAUSSE DE WATERLOO, 200, B-1640 RHODE-ST-GENESE</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>ZHANG, GUANGHUI</td>
											<td>4 MILLERS GROVE ROAD, BELLE MEAD, NJ 08502</td>
										</tr>
										<tr>
											<td>2</td>
											<td>PETERS, ROBIN</td>
											<td>24 KERSHAW COURT, BRIDGEWATER, NJ 08807</td>
										</tr>
										<tr>
											<td>3</td>
											<td>MARTINS, SONIA</td>
											<td>222 AMITY STREET, ELIZABETH, NJ 07202</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61L 15/32</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/US2005/037408</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2005-10-17</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>60/620,539</td>
									<td>2004-10-20</td>
								    <td>U.S.A.</td>
								</tr>
								<tr>
									<td>2</td>
									<td>60/696,258</td>
									<td>2005-07-01</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/253520-a-hemostat-to-provide-and-maintain-effective-hemostasis by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 12:41:40 GMT -->
</html>
